Bendamustine: More ammunition in the battle against mantle cell lymphoma

Leukemia and Lymphoma

Volumn 53, Issue 7, 2012, Pages 1249-1250

  Chang, Julie E ^a   Kahl, Brad S ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUORO 3 PHENYL 2 [1 (9H PURIN 6 YLAMINO)PROPYL] 3H QUINAZOLIN 4 ONE; BENDAMUSTINE; BORTEZOMIB; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRUTINIB; LENALIDOMIDE; OFATUMUMAB; PREDNISONE; RITUXIMAB; TEMSIROLIMUS; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; FEVER; HUMAN; INFECTION; MANTLE CELL LYMPHOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NOTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; NITROGEN MUSTARD COMPOUNDS;

EID: 84862746433     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.654342     Document Type: Note

References (13)

1. Leoni LM. Bendamustine: rescue of an effective antineo plastic agent from the mid-twentieth century. Semin Hematol 2011;48(Suppl. 1):S4-S11.
2. Lissitchkov T, Arnaudov G, Peytchev D, et al. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 2006;132:99-104. (Pubitemid 41752051)
3. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 2010;116: 106-114.
4. Warsch S, Hosein PJ, Maeda LS, et al. A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. Leuk Lymphoma 2012;53:1299-1305.
5. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473-4479.
6. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867-4874. (Pubitemid 46655613)
7. Inwards DJ, Fishkin PA, Hillman DW, et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer 2008;113:108-116. (Pubitemid 351980749)
8. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009;114(Suppl. 1): Abstract 405.
9. Temsirolimus, bendamustine and rituximab for relapsed follicular lymphoma or mantle cell lymphoma (NCT01078142). Bethesda, MD: National Institutes of Health; 2011. Available from: http://clinicaltrials.gov
10. Jerkeman M, Kolstad A, Laurell A, et al. Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: results from the phase I portion of the Nordic Lymphoma Group MLC4 (LENA-BERIT) Trial. Blood 2011;118(Suppl. 1): Abstract 2700.
11. Magni M, di Nicola M, Carlo-Stella C, et al. Safety, tolerability, and activity of ofatumumab, bendamustine, and dexamethasone combination as first-line treatment of mantle-cell lymphoma in the elderly: a multicenter study. Blood 2011;118(Suppl. 1): Abstract 1647.
12. Kahl B, Byrd JC, Flinn IW, et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 2010;116(Suppl. 1): Abstract 1777.
13. Wang L, Martin P, Blum KA, et al. The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. Blood 2011;118(Suppl. 1): Abstract 442.